


Umecrine Cognition Email Formats
Biotechnology Research • Nanna Svartz väg 6A (floor 4), Karolinska Institutet Science Park, Sweden • 11-20 Employees
Umecrine Cognition Email Formats
Umecrine Cognition uses 1 email format. The most common is {first name}.{last name} (e.g., john.doe@umecrine.se), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@umecrine.se | 100% |
Key Contacts at Umecrine Cognition
Viktor Drvota
Chief Executive Officer
Anders Karlsson
Chief Executive Officer
Camerini Roberto
Medical Director Consultant
Company overview
| Headquarters | Nanna Svartz väg 6A (floor 4), Karolinska Institutet Science Park, Solna, Stockholm County 171 65, SE |
| Phone number | +465566983655 |
| Website | |
| NAICS | 541714 |
| Keywords | Drug Development, Biotech, Fatigue, Neurological Disorders, Cognitive Function, Cognitive Disorders, Parkinsons Disease, pbc, Gabaa Receptor, Golexanolone, Hepatic Encephalopathy, Primary Biliary Cholangitis |
| Founded | 2000 |
| Employees | 11-20 |
| Socials |
About Umecrine Cognition
Umecrine Cognition is developing a completely new type of drug for neurological disorders in the brain that can occur as a result of a number of underlying diseases and lead to severely reduced cognition and alertness. The results from an internationally recognized clinical phase 2 study indicate that the company’s most advanced drug candidate, golexanolone, improves brain signaling and cognition and alertness in patients with hepatic encephalopathy. The continued development of golexanolone is initially focused on patient groups whose symptoms have arisen as a result of chronic liver diseases, but the mechanism of action is also relevant in a number of other indication areas. The results from an internationally recognized clinical phase 2 study indicate that the company’s most advanced drug candidate, golexanolone, improves brain signaling and cognition and alertness in patients with hepatic encephalopathy. The continued development of golexanolone is initially focused on patient groups whose symptoms have arisen as a result of chronic liver diseases, but the mechanism of action is also relevant in a number of other indication areas.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Umecrine Cognition has 6 employees across 4 departments.
Departments
Number of employees
Funding Data
Explore Umecrine Cognition's funding history, including investment rounds, total capital raised, and key backers.
Umecrine Cognition Tech Stack
Discover the technologies and tools that power Umecrine Cognition's digital infrastructure, from frameworks to analytics platforms.
CDN
JavaScript libraries
JavaScript libraries
Tag managers
Cookie compliance
Programming languages
Miscellaneous
Cookie compliance
Blogs
Miscellaneous
Hosting
Maps
Frequently asked questions
4.8
40,000 users



